Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage AD

Jeremy Pruzin MD
Cognitive/Behavioral Neurologist
Banner Alzheimer's Institute
Phoenix, AZ
Dr. Pruzin discloses that he is on the advisory board of Eisai, Inc.
Marwan Noel Sabbagh MD, FAAN, FANA
Moreno Family Chair of Alzheimer’s Research
Vice Chair for Research and Professor of Neurology
Director of the Applied Alzheimer’s Research Laboratory
Phoenix, AZ
Dr. Sabbagh discloses the following:
Ownership interest (Stock or stock options): NeuroTau, Optimal Cognitive Health Company, uMethod Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Lighthouse Pharmaceuticals, Alzheon, Reservoir Neuroscience
Consulting: Roche-Genentech, Eisai, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, Novo Nordisk, Corium, Prothena, KeiferRx, Anavex, Cognito Therapeutics
Royalties: Humanix
Board of Director: EIP Pharma
Grants and other Support:
PI: RO 1 AG059008
SABBAGH, MARWAN (PI)
09/01/18-05/31/24
A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease
LBDA1811MS
SABBAGH, MARWAN (PI)
05/15117-04/30/23
Research Center of Excellence (RCOE) designation
Site PI TRC-DS 1R61AG066543-01 (R61AG066543)
Site PI:ADRC- 1P30AG072980-01
Site PI: ADNI-U19AG024904
GC-2013717
SABBAGH, MARWAN (PI)
01/01/23-12/31127
Assessment of Lenalidomide for Alzheimer's Disease
R01 AG073212
SABBAGH, MARWAN (PI)
WILSON, JEFFREY (MPI)
DECOURT, BORIS (MPI)
Repurposing Siponimod for Alzheimer's Disease
4/1/21- 3/30/26